, Volume 66, Issue 2, pp 265-267
Date: 21 Oct 2009

Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access



Platinum-based therapy is the cornerstone of ovarian cancer treatment. Development of platinum hypersensitivity can limit therapeutic options. In this brief report, we present case of successful cisplatin administration following two unsuccessful carboplatin desensitization attempts, and without the need for pre-treatment steroids.


Retrospective chart review was performed.


One case of recurrent primary peritoneal carcinoma previously treated with a carboplatin-based regimen, developed a platinum hypersensitivity. Two attempts at carboplatin desensitization were unsuccessful. Cisplatin was substituted and the patient achieved a complete response to therapy without further hypersensitivity.


Platinum-based therapies are vital to the treatment of primary peritoneal and ovarian carcinoma. Protocols that successfully incorporate platinum agents, despite a platinum hypersensitivity, are clinically relevant.

D. P. Greene and J. S. Ferriss contributed equally to the research and final manuscript preparation.